Chargement en cours...

COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases

Although most autoimmune diseases are considered to be CD4 T cell‐ or antibody‐mediated, many respond to CD20‐depleting antibodies that have limited influence on CD4 and plasma cells. This includes rituximab, oblinutuzumab and ofatumumab that are used in cancer, rheumatoid arthritis and off‐label in...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Exp Immunol
Auteurs principaux: Baker, D., Roberts, C. A. K., Pryce, G., Kang, A. S., Marta, M., Reyes, S., Schmierer, K., Giovannoni, G., Amor, S.
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2020
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7405500/
https://ncbi.nlm.nih.gov/pubmed/32671831
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.13495
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!